Prognostic significance of mucin and P53 expression in stage ib non-small cell lung cancer: A laboratory companion study to CALGB 9633

Journal of Thoracic Oncology

Volumn 5, Issue 6, 2010, Pages 810-817

  Graziano, Stephen L ^a   Gu, Lin ^b   Wang, Xiaofei ^b   Tatum, Arthur H ^a   Vollmer, Robin T ^b   Strauss, Gary M ^c   Kratzke, Robert ^d   Dudek, Arkadiusz Z ^d   Vokes, Everett E ^e   Green, Mark R ^f  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c RHODE ISLAND HOSPITAL   (United States)

^d UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^e UNIVERSITY OF CHICAGO   (United States)

^f Southeast Cancer Control Consortium Inc   (United States)

Author keywords

Mucin; Non small cell lung cancer; P53; Prognostic factors

Indexed keywords

BLOOD GROUP A ANTIGEN; MUCIN; PROTEIN BCL 2; PROTEIN P53; TUMOR MARKER; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADENOCARCINOMA; ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DISEASE FREE SURVIVAL; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; SQUAMOUS CELL CARCINOMA; TUMOR VOLUME; CHEMISTRY; CLINICAL TRIAL; CONTROLLED STUDY; LUNG TUMOR; MIDDLE AGED; MORTALITY; NON SMALL CELL LUNG CANCER; PATHOLOGY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUCINS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-BCL-2; TUMOR SUPPRESSOR PROTEIN P53;

EID: 77953174764     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181d89f95     Document Type: Article

References (42)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics 2008. CA Cancer J Clin 2008;58:71-96.
2. WHO. Global cancer rates could increase 50% to 15 million by 2020 [WHO Web site] April 3, Global cancer rates could increase 50% to 15 million by 2020 [WHO Web site] April 3, 2003. Available at: http://www.who.int/mediacentre/news/ releases/2003/pr27/en. Accessed January 18, 2010.
3. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med 2004;350:351-360.
4. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med 2005;52:2589-2597. (Pubitemid 41007845)
5. Douillard JY, Rosell R, De Lena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]) : a randomised controlled trial. Lancet Oncol 2006;7:719-727.
6. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-3559.
7. Strauss GM, Herndon JE II, Maddus MA, et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups. J Clin Oncol 2008;26:5043-5051.
8. Harpole DH Jr, Herndon JE II, Wolfe WG, et al. A prognostic model of recurrence and death in stage I non-small cell lung cancer utilizing presentation, histopathology and oncoprotein expression. Cancer Res 1995;55:51-56.
9. Kwiatkowski DJ, Harpole DH, Godleski J, et al. Molecular pathologic substaging in 244 stage I non-small cell lung cancer patients: clinical implications. J Clin Oncol 1998;16:2468-2477.
10. Mehdi SA, Tatum AH, Newman NB, et al. Prognostic markers in resected stage I and II non-small-cell lung cancer: an analysis of 260 patients with 5 year follow-up. Clin Lung Cancer 1999;1:59-67.
11. Hsu SM, Raine L, Fanger H. Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques. J Histochem Cytochem 1981;29:577-580.
12. Graziano SL, Tatum AH, Newman NB, et al. The prognostic significance of neuroendocrine markers and carcinoembryonic antigen in patients with resected stage I and II non-small cell lung cancer. Cancer Res 1994;54:2908-2913.
13. Pezzella F, Turley H, Kuzu I, et al. bcl-2 protein in non-small cell lung carcinoma. N Engl J Med 1993;329:690-694.
14. Graziano SL, Tatum AH, Gonchoroff NJ, et al. Blood-group antigen A and flow cytometric analysis in resected early stage non-small cell lung cancer. Clin Cancer Res 1997;3:87-93.
15. Bancroft J, Stevens A. Theory and Practice of Histological Techniques, 2nd Ed. New York, NY: Churchill-Livingstone, 1982. Pp. 201-202.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Ass 1958;53:457-481.
17. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 1966;50:163-170.
18. Cox DR. Regression models and life tables. J R Stat Soc [B] 1972;34:187-200.
19. Ginsberg RJ, Vokes EE, Rosenzweig K. Non-small cell lung cancer. In DeVita VT Jr, Hellman S, Rosenberg SA. (Eds.), Cancer, Principles and Practice of Oncology, 6th Ed. Philadelphia, PA: Lippincott Williams & Wilkins, 2001. Pp. 925-983.
20. Gail MH, Eagan RT, Feld R, et al. Prognostic factors in patients with resected stage I non-small cell lung cancer: a report from the Lung Cancer Study Group. Cancer 1984;54:1802-1813.
21. Lipford EH III, Eggleston JC, Lillemoe KD, et al. Prognostic factors in surgically resected limited stage NSCLC. Am J Surg Pathol 1984;8:357-365.
22. Isobe H, Miyamoto H, Shimizu T, et al. Prognostic and therapeutic significance of flow cytometric nuclear DNA content in NSCLC. Cancer 1990;65:1391-1395.
23. Slebos RJ, Kebbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of lung. N Engl J Med 1990;323:561-565.
24. Lee JS, Ro JY, Sahin AA, et al. Expression of blood-group antigen-A: a favorable prognostic factor in non-small cell lung cancer. N Engl J Med 1991;324:1084-1090.
25. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma. J Natl Cancer Inst 1997;89:881-886.
26. Gajra A, Newman N, Gamble GP, et al. Impact of tumor size on survival in stage IA non-small cell lung cancer: a case for subdividing stage IA disease. Lung Cancer 2003;42:51-57.
27. Goldstraw P, Crowley J, Chansky K, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007;2:706-714. (Pubitemid 47357522)
28. Linnoila RI, Piantadosi S, Ruckdeschel JC. Impact of neuroendocrine differentiation in non-small cell lung cancer. The LCSG experience. Chest 1994;106:367s-371s.
29. Yu C, Shun C, Yan P, et al. Sialomucin expression is associated with erbB-2 oncoprotein overexpression, early recurrence, and cancer death in non-small cell lung cancer. Am J Respir Crit Care Med 1997;155:1419-1427.
30. Mitsudomi T, Hamajima H, Ogawa M, et al. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a metaanalysis. Clin Cancer Res 2000;6:4055-4063.
31. Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J 2001;18:705-719. (Pubitemid 33040631)
32. Sengupta S, Harris CC. p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol 2005;6:44-55.
33. Gajra A, Tatum AH, Newman N, et al. The predictive value of neuroendocrine markers and p53 for response to chemotherapy and survival in patients with advanced non-small cell lung cancer. Lung Cancer 2002;36:159-165.
34. Nakanishi H, Matsumoto S, Iwakawa R, et al. Whole genome comparison of allelic imbalances between noninvasive and invasive small-sized lung adenocarcinomas. Cancer Res 2009;69:1615-1623.
35. Tsao MS, Aviel-Ronen S, Ding K, et al. Prognostic and predictive importance of p53 and ras for adjuvant chemotherapy in non-small-cell lung cancer. J Clin Oncol 2007;25:5240-5247.
36. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006;355:983-989.
37. Filipits M, Pirker R, Dunant A, et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected nonsmall-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol 2007;25:2735-2740. (Pubitemid 47123181)
38. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007;356:800-808.
39. Potti A, Mukherjee S, Petersen R, et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med 2006;355:570-580.
40. Azzoli CG, Park BJ, Pao W, et al. Molecularly tailored adjuvant chemotherapy for resected non-small cell lung cancer; a time for excitement and equipoise. J Thorac Oncol 2008;3:84-93.
41. Seve P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR. 10. Clin Cancer Res 2007;13:994-999.
42. Rosell R, Skrzypski M, Jassem E, et al. BRCA1: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007;2: e1129.